Janux Therapeutics Inc. (JANX) NASDAQ
$47.10 (0.41) (-0.86%)
Market Cap: $2.44B
As of 05/17/24 04:00 PM EDT. Market closed.
Janux Therapeutics Inc. (JANX)
NASDAQ
$47.10
(0.41) (-0.86%)
Market Cap: $2.44B
As of 05/17/24 04:00 PM EDT. Market closed.
Add to Portfolio
janux therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary tumor activated t cell engager (tractr) platform technology to better treat patients suffering from cancer. janux’s initial focus is on developing a novel class of t cell engagers (tces), and its lead product candidates are designed to target clinically validated drug ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
David Alan Campbell
Full Time Employees
9
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
David Alan Campbell
Full Time Employees
9
URL
Address
10955 Vista Sorrento Parkway, Suite 200, CA, San Diego, 92130.
PRICE CHART FOR JANUX THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$47.44
Previous Close
$47.51
Days Range
$46.79 - $47.86
52 week range
$5.65 - $65.60
Volume
698,030
Avg. Volume (30 days)
905,828
Market Cap
$2.44B
Dividend Yield
-
P/E
(43.93)
Shares Outstanding
51,850,667
Open
$47.44
Previous Close
$47.51
Days Range
$46.79 - $47.86
52 week range
$5.65 - $65.60
Volume
698,030
Avg. Volume (30 days)
905,828
Market Cap
$2.44B
Dividend Yield
-
P/E
(43.93)
Shares Outstanding
51,850,667
FINANCIAL STATEMENTS FOR JANUX THERAPEUTICS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR JANUX THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Reardon Tighe | Acting Chief Financial Officer | Nov 13, 2023 | Buy | $5.87 | 849,854 | 4,988,643 | 849,854 | Nov 15, 2023, 04:48 PM |
| Lichter Jay | Director | Nov 13, 2023 | Buy | $5.87 | 849,854 | 4,988,643 | 849,854 | Nov 15, 2023, 04:46 PM |
| Avalon Ventures XI, L.P. | 10% Owner | Nov 13, 2023 | Buy | $5.87 | 849,854 | 4,988,643 | 849,854 | Nov 13, 2023, 07:11 PM |
| RA CAPITAL MANAGEMENT, L.P. | Director | Jul 19, 2023 | Buy | $12.46 | 495,008 | 6,167,800 | 8,117,246 | Jul 21, 2023, 04:31 PM |
| ORBIMED ADVISORS LLC | Director | Dec 29, 2021 | Sale | $20.30 | 40,400 | 820,120 | 2,258,566 | Dec 30, 2021, 09:00 PM |
| Thompson Peter A. | Director | Dec 29, 2021 | Sale | $20.30 | 40,400 | 820,120 | 2,258,566 | Dec 30, 2021, 08:55 PM |
| ORBIMED ADVISORS LLC | Director | Dec 21, 2021 | Sale | $19.00 | 119,400 | 2,268,600 | 2,295,266 | Dec 23, 2021, 04:13 PM |
| Thompson Peter A. | Director | Dec 21, 2021 | Sale | $19.00 | 119,400 | 2,268,600 | 2,295,266 | Dec 23, 2021, 04:08 PM |
| Thompson Peter A. | Director | Dec 16, 2021 | Sale | $19.07 | 393,300 | 7,500,231 | 2,403,566 | Dec 17, 2021, 05:16 PM |
| ORBIMED ADVISORS LLC | Director | Dec 16, 2021 | Sale | $19.07 | 393,300 | 7,500,231 | 2,403,566 | Dec 17, 2021, 05:13 PM |
| Thompson Peter A. | Director | Jun 15, 2021 | Buy | $17.00 | 705,853 | 11,999,501 | 2,760,366 | Jun 16, 2021, 06:20 PM |
| Reardon Tighe | Acting Chief Financial Officer | Jun 15, 2021 | Buy | $17.00 | 629,411 | 10,699,987 | 4,479,492 | Jun 16, 2021, 06:11 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Reardon Tighe | Acting Chief Financial Officer | 11/13/2023 | 4,988,643 |
| Lichter Jay | Director | 11/13/2023 | 4,988,643 |
| Avalon Ventures XI, L.P. | 10% Owner | 11/13/2023 | 4,988,643 |
| RA CAPITAL MANAGEMENT, L.P. | Director | 07/19/2023 | 6,167,800 |
| ORBIMED ADVISORS LLC | Director | 12/29/2021 | 820,120 |
| Thompson Peter A. | Director | 12/29/2021 | 820,120 |
| ORBIMED ADVISORS LLC | Director | 12/21/2021 | 2,268,600 |
| Thompson Peter A. | Director | 12/21/2021 | 2,268,600 |
| Thompson Peter A. | Director | 12/16/2021 | 7,500,231 |
| ORBIMED ADVISORS LLC | Director | 12/16/2021 | 7,500,231 |
| Thompson Peter A. | Director | 06/15/2021 | 11,999,501 |
| Reardon Tighe | Acting Chief Financial Officer | 06/15/2021 | 10,699,987 |
Load More Insider Transactions
FUNDS WITH A POSITION IN JANUX THERAPEUTICS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9,165,652 | 4.42% | No change | Other |
| ORBIMED ADVISORS LLC | 4,275,553 | 2.95% | 28.86% | Other |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,775,672 | 0.2% | 104.77% | Other |
| BLACKROCK INC. | 1,693,991 | 0.00148% | -3.87% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 467,547 | 0.00163% | 14.54% | Other |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 191,055 | 0.07% | New | Growth |
| RENAISSANCE TECHNOLOGIES LLC | 92,899 | 0.0055% | New | Other |
| CANDRIAM S.C.A. | 80,005 | 0.02% | New | Other |
| D. E. SHAW & CO., INC. | 54,638 | 0.00176% | New | Other |
| TUDOR INVESTMENT CORP ET AL | 6,415 | 0.00154% | New | Event Driven, Other |
CHANGE IN SHARES OUTSTANDING FOR JANUX THERAPEUTICS INC
STOCK BUYBACKS FOR JANUX THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 03/31/2024
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
12/31/2023
5.00%
1Q
09/30/2023
7.31%
2Q
06/30/2023
17.24%
3Q
03/31/2023
17.45%
4Q
12/31/2022
17.95%
5Q
09/30/2022
18.12%
6Q
06/30/2022
18.34%
7Q
03/31/2022
18.72%
8Q
09/30/2021
19.24%
10Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR JANUX THERAPEUTICS INC
LOADING...